New study with Salipro® - Reprogramming Cancer Cells to Fight Themselves

We are excited to share a new study published in Cell Discovery that opens new avenues in cancer treatment by reprogramming cancer metabolism to enhance immune responses and fight tumors.

Targeting complex membrane protein assemblies - like the Basigin-MCT transporter - has long been a major challenge in oncology. Understanding how to modulate their function is critical for creating effective new therapies. The study introduces a novel antibody that reprograms the basigin protein, transforming it from a tumor enabler into a suppressor of the cancer’s metabolic fuel supply.

With the Salipro® platform, the researchers achieved high-resolution cryo-EM and molecular dynamics simulations, revealing the precise mechanism by which the antibody modulates MCT1 and MCT4 transporters.

This structural insight provides a detailed map of the antibody-protein interaction, paving the way for more precise medicines with potentially fewer side effects.

Congratulations to the teams for their contribution to the fields of cancer biology and structural immunology!

Find the full study:
H. Zhang, et al., A basigin antibody modulates MCTs to impact tumor metabolism and immunity. Cell Discovery, (2025).